Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer Bone Metastases in Subjects With Advanced Breast Cancer Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Keywords: Bone metastases Hormone-refractory prostate cancer Multiple myeloma Denosumab Breast cancer 20050103 20050136 20050244 Advanced cancer Tumor Prostate cancer Zoledronic acid
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 35
Healthy volunteers: no

Brief summary:
The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: amg 162
Intervention descriptions: intervention 1: 120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.

Protocol document: